Breast Cancer

Rutqvist, Lars‐Erik

doi:10.3109/02841869609101663

Cited by 5 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 1970s, breast conservative surgery in combination with postoperative radiotherapy was introduced. During the following decades, utilization of this treatment method increased and it is now dominant [ 21 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…The database includes information from the Swedish Cancer Register, the Swedish Cause-of-Death register and the Swedish Population register. The Swedish Cancer Register is mandatory for all malignant diagnoses and contains data from 1958 [ 21 ]. It includes data on social security number, sex, place of residency at diagnosis, reporting hospital and clinic, date of diagnosis, clinical and morphological diagnosis, and extent of tumor at diagnosis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study

Karlsson

Granath

Smedby

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Sarcomas of the breast account for about 1% of all breast malignancies. The aim of this national survey was to explore etiologic and prognostic factors. Methods Utilizing national Swedish registers, all patients registered with mesenchymal tumors in the breast during the period 1993–2013 (n = 344) were identified and compared to up to ten age and gender matched controls. Cancer history was retrieved for cases and controls. Conditional Poisson regression models were used for calculation of odds ratios. Results Previous breast cancer was overrepresented among patients with angiosarcoma. The highest risk occurred ≥ 5 years after treatment for breast cancer (OR 73.9, 95% confidence interval, CI, 25.4–215; P < 0.001). An increase in incidence of angiosarcoma was observed during the study period (1.10, 95% CI 1.05–1.16; P < 0.001). The overall incidence of breast sarcoma increased from 1.52 to 2.04 cases per million per year. Angiosarcoma of the breast was associated with a significant excess mortality compared to age-matched controls (HR 4.65, 95% CI 3.01–7.19; P < 0.001). Conclusions Angiosarcoma increased in incidence and displayed a more severe clinical course, with significantly shorter survival. The strong association between a history of breast cancer 5 years or more prior to the diagnosis of angiosarcoma points to radiotherapy as a contributing factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study

Karlsson

Granath

Smedby

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Evidence from randomised clinical trials suggests that the use of radiotherapy (RT) is associated with a significantly lower rate of local recurrence in patients treated with BCS (EBCTCG, 2000). Achieving local tumour control is important as relapse often leads to removal of the breast and can result in uncontrolled local disease (Rutqvist, 1996). A causal relationship between local recurrence and distant metastasis has been suggested (Cowen et al, 2000), but the meta-analyses and individual clinical trials have so far yielded conflicting results about the survival advantage due to adjuvant RT ( Van de Steene et al, 2000).…”

mentioning

confidence: 99%

Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery

et al. 2004

View full text Add to dashboard Cite

The adequate timing of adjuvant radiotherapy (RT) in breast cancer has become a subject of increasing interest in recent years. A population-based study was undertaken to determine the influence of demographic and clinical factors on the postoperative RT delay in patients treated with breast-conserving surgery (BCS) and to assess the impact of delay on survival. In total, 7800 breast cancer patients treated with BCS and adjuvant RT between 1986 and 1998 in Yorkshire were included in the study. The median interval between surgery and the start of RT (S -RT interval) was 8 weeks (7 weeks for chemotherapy negative and 11 for chemotherapy positive patients). This interval increased substantially over time from 5 weeks during 1986 -1988, irrespective of patients' chemotherapy status, to 10 and 17 weeks among chemotherapy negative and chemotherapy positive patients, respectively, in 1997 -1998. The S -RT interval was also significantly influenced by travel time to RT centre, year and at which RT centre patient had the treatment (Po0.001). Overall, 5-year survival was 82%. Patients with S -RT intervals longer than 9 weeks had a trend towards an increased relative risk of death. This reached a statistical significance at 20 -26 weeks (RR 1.49, 95% CI (1.16 -1.92)). The findings of our study suggest that delaying the initiation of RT for 20 -26 weeks after surgery is associated with decreased survival in patients treated with conservation surgery.

show abstract

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Schmitz

Troxel

Cheville

et al. 2009

Contemporary Clinical Trials

122

125

View full text Add to dashboard Cite

Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.

show abstract

Breast Cancer

Cited by 5 publications

References 81 publications

Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study

Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study

Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Contact Info

Product

Resources

About